NCT06216938View on ClinicalTrials.gov

RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 7, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2027

Conditions
Melanoma
Interventions
BIOLOGICAL

Vusolimogene oderparepvec (RP1)

Vusolimogene Oderparepvec is a genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virus, with potential oncolytic, immunostimulating and antineoplastic activities.

Trial Locations (1)

15232

RECRUITING

UPMC Hillman Cancer Center, Pittsburgh

All Listed Sponsors
collaborator

Replimune Inc.

INDUSTRY

lead

Yana Najjar

OTHER